Complete or partial tumour regression after chemoradiotherapy, as determined by the clinical follow-up, was observed in 69.6% of the tumours that were positive for CHK2 expression, but only in 32.1% of tumours that were negative for CHK2 expression (P=0.011). The gene discussed is CHEK2; the disease is neoplasm.